Neoadjuvant docetaxel, oxaliplatin and S‑1 (DOS) combination chemotherapy for patients with resectable adenocarcinoma of esophagogastric junction
Takuro Saito, Yukinori Kurokawa, Tsuyoshi Takahashi, Kazuyoshi Yamamoto, Kotaro Yamashita, Koji Tanaka, Tomoki Makino, Kiyokazu Nakajima, Hidetoshi Eguchi, Yuichiro� Doki
Topics & Concepts
MedicineDocetaxelOxaliplatinInternal medicineNeoadjuvant therapyNeutropeniaSurgical oncologyFebrile neutropeniaChemotherapyAdenocarcinomaGastroenterologyEpirubicinSurgeryOncologyCancerColorectal cancerCyclophosphamideBreast cancerEsophageal Cancer Research and TreatmentGastric Cancer Management and OutcomesPancreatic and Hepatic Oncology Research